
ROIV Stock Forecast & Price Target
ROIV Analyst Ratings
Bulls say
Roivant Sciences Ltd demonstrates a robust outlook due to the promising commercial stage of its drug candidate VTAMA for treating plaque psoriasis, along with positive Phase 3 results for brepocitinib in dermatomyositis (DM), which highlights its efficacy and a significant improvement in delivery methods compared to existing therapies. The company has raised revenue estimates for IMVT-1402 in Graves' Disease, reflecting strong investor sentiment towards its clinical advancements and the potential for successful commercialization of its diverse pipeline, including Batoclimab, which is uniquely positioned as a disease-modifying therapy in Graves' patients. Overall, these factors contribute to a favorable assessment of Roivant's growth prospects within the biopharmaceutical sector.
Bears say
The financial outlook for Roivant Sciences is negatively impacted by the recent failure of key drug candidates in clinical trials, including the IMVT assets and brepocitinib, which raises concerns about the company's pipeline viability and long-term growth potential. Additionally, the uncertainty surrounding the efficacy and safety of remaining candidates, such as the off-target effects related to TSHR antagonism, adds further risk to future product development. The prevalence of unmet medical needs in key indications underscores the potential challenges Roivant faces in differentiating its treatments and capturing market share amid increasing competition.
This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.
ROIV Analyst Forecast & Price Prediction
Start investing in ROIV
Order type
Buy in
Order amount
Est. shares
0 shares